JNJ
$144.75
Johnson & Johnson
$.28
.19%
JNJ
Earnings Whisper ®
N/A
4th Quarter December 2024
Consensus:  $2.00
Revenue:  $22.54 Bil
Wednesday
Jan 22
6:20 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Tuesday, October 15, 2024

What do you expect when JNJ reports earnings?
Beat
Meet
Miss

Where is JNJ's stock price going from here?
Up
Flat
Down
Stock chart of JNJ
Analysts
Summary of analysts' recommendations for JNJ
Score
Grade
Pivots
Resistance
$147.37
$146.09
$145.42

$144.14

Support
$143.47
$142.19
$141.52
Tweet
Growth
Description
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Peers
Vertex PharmaceuticalsBioMarin PharmaceuticalARRAY TechnologiesRegeneron PharmaceuticalsMerck & Co.Bristol Myers SquibbEli LillyPfizerUltragenyx PharmaceuticalZoetis